Zymeworks Inc. Files 8-K: Board & Officer Changes
Ticker: ZYME · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1937653
Sentiment: neutral
Topics: leadership-change, executive-compensation, filing
TL;DR
Zymeworks filed an 8-K on 4/3/24 detailing board and exec changes, plus compensation.
AI Summary
On April 3, 2024, Zymeworks Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on the election of new directors and the appointment of certain officers, as well as details regarding compensatory arrangements for these individuals. The report also covers financial statements and exhibits.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and executive compensation can introduce uncertainty and signal potential strategic shifts, warranting closer investor scrutiny.
Key Numbers
- 001-41535 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- April 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
Who were the specific individuals elected as new directors or appointed as officers?
The filing indicates changes in directors and officers but does not name the specific individuals in the provided text.
What are the details of the compensatory arrangements for the newly appointed officers?
The filing mentions compensatory arrangements but does not provide specific details on the amounts or terms in the provided text.
What is the effective date of these board and officer changes?
The date of the earliest event reported is April 3, 2024.
Are there any financial statements included with this filing?
Yes, the filing indicates that financial statements and exhibits are included.
What is the primary business of Zymeworks Inc. according to the filing?
Zymeworks Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 841 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-04-03 19:25:56
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $425,000 — oing covenants, including: Payment of $425,000, less applicable withholdings, equivale
Filing Documents
- d821869d8k.htm (8-K) — 28KB
- d821869dex101.htm (EX-10.1) — 31KB
- 0001193125-24-086214.txt ( ) — 188KB
- zyme-20240403.xsd (EX-101.SCH) — 3KB
- zyme-20240403_lab.xml (EX-101.LAB) — 18KB
- zyme-20240403_pre.xml (EX-101.PRE) — 11KB
- d821869d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: April 3, 2024 By: /s/ Kenneth Galbraith Name: Kenneth Galbraith Title: Chair, President, Chief Executive Officer and interim Chief Financial Officer 3